The Role of CTLA-4 Exon-1 49 A/G Polymorphism and Soluble CTLA-4 Protein Level in Egyptian Patients with Behçet's Disease

Table 4

CTLA-4 genotypes and allele frequencies in relation to some clinical manifestations of Behçet's disease in Egyptian patients.

CTLA-4 49 A	Genotypes frequency, 𝑛 (%)			Alleles frequency, 𝑛 (%)
	AA	AG	GG	A	G
Skin pathergy
With	23 (60.5)*	13 (34.2)	2 (5.3)	59 (77.6)^#	17 (22.4)
Without	8 (36.4)	8 (36.4)	6 (27.3)	24 (54.5)	20 (45.5)
Retinopathy
With	21 (60.0)†	12 (34.3)	2 (5.7)	54 (77.1)¶	16 (22.9)
Without	14 (40.0)	9 (36.0)	6 (24.0)	29 (58.0)	21 (42.0)
Vasculitis
With	22 (61.1)♯	12 (33.3)	2 (5.6)	56 (77.8)§	16 (22.2)
Without	9 (37.5)	9 (37.5)	6 (25.0)	27 (56.2)	21 (43.8)

^∗𝑃 value = 0.018; odds ratio = 8.63 in patients with versus without skin pathergy test.
^#𝑃 value = 0.009; odds ratio = 2.89 in patients with versus without skin pathergy test.
^†𝑃 value = 0.041; odds ratio = 6.31 in patients with versus without retinopathy.
^¶𝑃 value = 0.027; odds ratio = 2.44 in patients with versus without retinopathy.
^♯𝑃 value = 0.028; odds ratio = 7.33 in patients with versus without vasculitic manifestations.
^§𝑃 value = 0.014; odds ratio = 2.72 in patients with versus without vasculitic manifestations.